Trends in Recommendations of Myelosuppressive Chemotherapy for the Treatment of Breast Cancer: Evolution of the National Comprehensive Cancer Network Guidelines and the Cooperative Group Studies-Reference-Cited by-同舟云学术

Trends in Recommendations of Myelosuppressive Chemotherapy for the Treatment of Breast Cancer: Evolution of the National Comprehensive Cancer Network Guidelines and the Cooperative Group Studies

Published:2006-04 Issue:1 Volume:7 Page:33-41
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Rivera Edgardo,Smith Robert E.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference49 articles.

1. Cancer statistics, 2005 [published erratum in CA Cancer J Clin 2005; 55:259];Jemal;CA Cancer J Clin,2005

2. Cancer Prevention & Early Detection Facts & Figures 2004;American Cancer Society,2004

3. Trends in late-stage breast, cervical and colorectal cancers in blacks and whites;Polednak;Ethn Dis,2000

4. Diagnosis, clinical staging, and treatment of breast cancer: a retrospective multiyear study of a large controlled population;Legorreta;Am J Clin Oncol,2004

5. Secular trends in the incidence of female breast cancer in the United States, 1973-1998;Nasseri;Breast J,2004

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemcitabine and doxorubicin in immunostimulatory monophosphoryl lipid A liposomes for treating breast cancer;Bioengineering & Translational Medicine;2020-09-16

2. Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial;Breast Cancer Research and Treatment;2019-03-21

3. Incidence and attributes of chemotherapy induced myelotoxicity, anemia and neutropenia in adults with cancer in Nepal: A cross-sectional observational study;Journal of Oncology Pharmacy Practice;2018-12-11

4. Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study;Breast Cancer Research and Treatment;2017-02-07

5. Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis;BMC Health Services Research;2014-04-27